Cargando…

Effects of CYP3A Inhibition, CYP3A Induction, and Gastric Acid Reduction on the Pharmacokinetics of Ripretinib, a Switch Control KIT Tyrosine Kinase Inhibitor

Ripretinib is a switch control KIT kinase inhibitor approved for treatment of adults with advanced gastrointestinal stromal tumors who received prior treatment with 3 or more kinase inhibitors, including imatinib. Ripretinib and its active metabolite (DP‐5439) are cleared mainly via cytochrome P450...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Xiaoyan, Shelton, Mark J, Wang, Jing, Meade, Julie, Ruiz‐Soto, Rodrigo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9790248/ https://www.ncbi.nlm.nih.gov/pubmed/35560823 http://dx.doi.org/10.1002/cpdd.1110

Ejemplares similares

Efficacy and safety of ripretinib in patients with KIT-altered metastatic melanoma
por: Janku, F., et al.
Publicado: (2022)

Switch Control Inhibition of KIT and PDGFRA in Patients With Advanced Gastrointestinal Stromal Tumor: A Phase I Study of Ripretinib
por: Janku, Filip, et al.
Publicado: (2020)

Effects of Strong CYP2C8 or CYP3A Inhibition and CYP3A Induction on the Pharmacokinetics of Brigatinib, an Oral Anaplastic Lymphoma Kinase Inhibitor, in Healthy Volunteers
por: Tugnait, Meera, et al.
Publicado: (2019)

Effect of the Most Relevant CYP3A4 and CYP3A5 Polymorphisms on the Pharmacokinetic Parameters of 10 CYP3A Substrates
por: Saiz-Rodríguez, Miriam, et al.
Publicado: (2020)

Effect of CYP3A4*22, CYP3A5*3, and CYP3A Combined Genotypes on Cyclosporine, Everolimus, and Tacrolimus Pharmacokinetics in Renal Transplantation
por: Moes, D J A R, et al.
Publicado: (2014)

Phase I Studies of Acebilustat: Pharmacokinetics, Pharmacodynamics, Food Effect, and CYP3A Induction
por: Elborn, JS, et al.
Publicado: (2016)

Pharmacokinetics of asciminib in the presence of CYP3A or P‐gp inhibitors, CYP3A inducers, and acid‐reducing agents
por: Hoch, Matthias, et al.
Publicado: (2022)

Clinical Activity of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumor Harboring Heterogeneous KIT/PDGFRA Mutations in the Phase III INVICTUS Study
por: Bauer, Sebastian, et al.
Publicado: (2021)

Variants in COMT, CYP3A5, CYP2B6, and ABCG2 Alter Quetiapine Pharmacokinetics
por: Zubiaur, Pablo, et al.
Publicado: (2021)

Effect of CYP3A4(∗)1G and CYP3A5(∗)3 Polymorphisms on Pharmacokinetics and Pharmacodynamics of Ticagrelor in Healthy Chinese Subjects
por: Liu, Shuaibing, et al.
Publicado: (2017)

Ripretinib: First Approval
por: Dhillon, Sohita
Publicado: (2020)

CYP3A4 and CYP3A5 genotyping by Pyrosequencing
por: Garsa, Adam A, et al.
Publicado: (2005)

Effect of CYP3A4*22, CYP3A5*3, and CYP3A combined genotypes on tamoxifen metabolism
por: Sanchez Spitman, A. B., et al.
Publicado: (2017)

The Effects of Weak and Strong CYP3A Induction by Rifampicin on the Pharmacokinetics of Five Progestins and Ethinylestradiol Compared to Midazolam
por: Wiesinger, Herbert, et al.
Publicado: (2020)

Potential Role of Patients’ CYP3A-Status in Clozapine Pharmacokinetics
por: Tóth, Katalin, et al.
Publicado: (2017)

Intentional Modulation of Ibrutinib Pharmacokinetics through CYP3A Inhibition
por: Eisenmann, Eric D., et al.
Publicado: (2021)

Enantioselective pharmacokinetics of tramadol and its three main metabolites; impact of CYP2D6, CYP2B6, and CYP3A4 genotype
por: Haage, Pernilla, et al.
Publicado: (2018)

MD Investigation on the Interaction between Carbamazepine and Two CYP Isoforms, CYP3A4 and CYP3A5
por: Liu, Shuhui, et al.
Publicado: (2023)

Influence of CYP2D6 and CYP3A5 Polymorphisms on the Pharmacokinetics and Pharmacodynamics of Bisoprolol in Hypertensive Chinese Patients
por: Chan, Sze Wa, et al.
Publicado: (2021)

Polymorphisms in the cytochrome P450 genes CYP1A2, CYP1B1, CYP3A4, CYP3A5, CYP11A1, CYP17A1, CYP19A1 and colorectal cancer risk
por: Bethke, Lara, et al.
Publicado: (2007)

CYP3A and CYP2C19 activity in urine in relation to CYP3A4, CYP3A5, and CYP2C19 polymorphisms in Russian peptic ulcer patients taking omeprazole
por: Denisenko, Natalia P, et al.
Publicado: (2018)

Influence of FMO3 and CYP3A4 Polymorphisms on the Pharmacokinetics of Teneligliptin in Humans
por: Park, Jin-Woo, et al.
Publicado: (2021)

Atractylodes lancea for cholangiocarcinoma: Modulatory effects on CYP1A2 and CYP3A1 and pharmacokinetics in rats and biodistribution in mice
por: Muhamad, Nadda, et al.
Publicado: (2022)

Multi-disciplinary management of recurrent gastrointestinal stromal tumor harboring KIT exon 11 mutation with the switch-control kinase inhibitor ripretinib and surgery
por: Gouda, Mohamed A., et al.
Publicado: (2023)

A PBPK Model to Predict Disposition of CYP3A-Metabolized Drugs in Pregnant Women: Verification and Discerning the Site of CYP3A Induction
por: Ke, A B, et al.
Publicado: (2012)

The roles of Cyp1a2 and Cyp2d in pharmacokinetic profiles of serotonin and norepinephrine reuptake inhibitor duloxetine and its metabolites in mice
por: Qin, Xuan, et al.
Publicado: (2023)

Assessment of the Effects of Inhibition or Induction of CYP2C19 and CYP2C9 Enzymes, or Inhibition of OAT3, on the Pharmacokinetics of Abrocitinib and Its Metabolites in Healthy Individuals
por: Wang, Xiaoxing, et al.
Publicado: (2022)

Pregnane X Receptor and Yin Yang 1 Contribute to the Differential Tissue Expression and Induction of CYP3A5 and CYP3A4
por: Nem, Dieudonné, et al.
Publicado: (2012)

Impact of CYP3A4*22 on Pazopanib Pharmacokinetics in Cancer Patients
por: Bins, Sander, et al.
Publicado: (2018)

Effects of tomato juice on the pharmacokinetics of CYP3A4-substrate drugs
por: Ohkubo, Atsuko, et al.
Publicado: (2017)

Correction to: Ripretinib: First Approval
por: Dhillon, Sohita
Publicado: (2020)

Ripretinib for gastrointestinal stromal tumours
Publicado: (2021)

Screening of Genetic Polymorphisms of CYP3A4 and CYP3A5 Genes
por: Lee, Jin Sol, et al.
Publicado: (2013)

Effects of Ninjin'yoeito on Human CYP3A and Mouse CYP3A Activity
por: Kaneda, Marisa, et al.
Publicado: (2023)

Reductive metabolism of oxymatrine is catalyzed by microsomal CYP3A4
por: Liu, Wenqin, et al.
Publicado: (2015)

Pharmacokinetics of the CYP3A4 and CYP2B6 Inducer Carbamazepine and Its Drug–Drug Interaction Potential: A Physiologically Based Pharmacokinetic Modeling Approach
por: Fuhr, Laura Maria, et al.
Publicado: (2021)

Phase I study to assess the effect of adavosertib (AZD1775) on the pharmacokinetics of substrates of CYP1A2, CYP2C19, and CYP3A in patients with advanced solid tumors
por: Någård, Mats, et al.
Publicado: (2023)

Prediction of Metabolic Interactions With Oxycodone via CYP2D6 and CYP3A Inhibition Using a Physiologically Based Pharmacokinetic Model
por: Marsousi, N, et al.
Publicado: (2014)

Impact of Pomegranate Juice on the Pharmacokinetics of CYP3A4- and CYP2C9-Mediated Drugs Metabolism: A Preclinical and Clinical Review
por: Mansoor, Kenza, et al.
Publicado: (2023)

Predictiveness of the Human-CYP3A4-Transgenic Mouse Model (Cyp3aXAV) for Human Drug Exposure of CYP3A4-Metabolized Drugs
por: Damoiseaux, David, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_bdi55ofhslmeegs0909cpert9g